E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Multicentric Castleman's disease |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10050251 |
E.1.2 | Term | Castleman's disease |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to demonstrate that CNTO 328 in combination with BSC is superior to BSC in terms of objective response (complete response [CR] + partial response [PR]) among subjects with multicentric Castleman’s disease (MCD). |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are: • To demonstrate additional measures of efficacy (duration of tumor response; time to treatment failure; change in hemoglobin levels; ability to discontinue corticosteroids; and improvement in fatigue, physical function, and other disease-related symptoms) • To study the safety of prolonged dosing • To determine the pharmacokinetics of CNTO 328 among subjects with MCD • To determine a baseline hepcidin value predictive of a ≥ 2 g/dL increase in hemoglobin |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Measurable and symptomatic MCD proven by biopsy. Symptomatic disease is defined clinically by the presence of symptoms or by marked laboratory abnormalities with NCI-CTCAE grading ≥ 1 that are attributable to the disease, and for which treatment is indicated. Subjects are required to have measurable disease, which may be limited to cutaneous lesions. Elevations in acute-phase proteins (CRP, fibrinogen) and increased ESR in the absence of other symptoms do not qualify as symptomatic disease. 2. ≥ 18 years of age 3. Pretreatment clinical laboratory values meeting these criteria within 4 weeks before treatment: a. Absolute neutrophil count (ANC) ≥ 1.0 x 109/L b. Platelets ≥ 75 x 109/L c. ALT; unfractionated alkaline phosphatase within 2.5 x ULN; if above 2.5 x ULN, subjects will be eligible if alkaline phosphatase liver fraction is within 2.5 x ULN; total bilirubin within 2.5 x ULN d. Serum creatinine ≤ 3.0 mg/dL 4. ECOG Performance Status of 0, 1, or 2 5. Corticosteroids dose that does not exceed 1 mg/kg/day of prednisone (or equivalent) and has remained stable or decreased over the 4 weeks before enrollment 6. Subjects of childbearing potential must use adequate birth control measures. Negative pregnancy test (serum or urine beta human chorionic gonadotropin [β-HCG]) at screening (applicable to women of childbearing potential). 7. Subjects (or their legally-acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. Informed consent must be obtained before performing any study-specific procedures. |
|
E.4 | Principal exclusion criteria |
1. HIV or HHV-8 positive 2. Previous lymphoma 3. Malignancies, except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or cancer other than lymphoma, from which the subject has been disease-free for ≥ 3 years. 4. Concurrent medical condition or disease (eg, autoimmune disease, active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study 5. Use of disallowed therapies: other concomitant anti-tumor therapies for Castleman’s disease (eg, anti-CD20 antibodies, IL-6- or IL-6 receptor-targeted therapies, chemotherapy), biologic treatments such as anti-tumor necrosis factor α (TNFα) antibodies, immunosuppressive agents (except stable doses of corticosteroids), and erythropoietin stimulating agents (ESAs) 6. Received an investigational drug (including vaccines), or received any systemic treatment for Castleman’s disease within 4 weeks (or in the case of rituximab, within 8 weeks) before the planned start of treatment 7. Major surgery within 4 weeks of treatment 8. History of uncontrolled heart disease such as unstable angina, congestive heart failure, myocardial infarction within preceding 12 months, hemodynamic instability or known left ventricular ejection fraction (LVEF) < 30%, or clinically significant rhythm or conduction abnormality 9. Clinically significant infections, including known hepatitis C infection or known to be hepatitis B surface antigen (HBsAg) positive 10. History of allogeneic transplant (except corneal transplants) 11. Known allergies, hypersensitivity, or intolerance to monoclonal antibodies or to murine, chimeric, or human proteins or their excipients 12. Pregnant or nursing 13. Vaccination with live, attenuated vaccines within 4 weeks of first administration of study agent 14. Paraneoplastic pemphigus or bronchiolitis obliterans 15. Any condition that, in the opinion of the investigator, would compromise the wellbeing of the subject or the study or prevent the subject from meeting or performing study requirements |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint will be objective tumor response (CR + PR) modified to allow assessment of measurable cutaneous lesions, as measured by Cheson criteria (Cheson et al, 2007; positron-emission tomography [PET] scan data, if obtained, will not be taken into account). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as one year after the last subject starts study treatment. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 25 |